Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 97

Sort by

Sort Order Select

Journal Articles

Age-Related Cellular Factors Facilitate TET2 Mutant Clonal Hematopoiesis

Daniel J Vail, Dongxu Jiang, Kunho Chung, Yahan Zhang, Sophia Martinez, Luca Guarnera, Yvonne Parker, J. Joseph Melenhorst, Daniel Lindner, Jaroslaw Maciejewski, Babal K. Jha

Blood (2024) 144 (Supplement 1): 1278.

https://doi.org/10.1182/blood-2024-211683

Published: 2024

Journal Articles

Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy

Benjamin F. Frost, Noelle Frey, Elizabeth O. Hexner, Stephen J. Schuster, Sunita D. Nasta, Alison W Loren, Jakub Svoboda, Daniel J. Landsburg, Bruce Levine, Joseph A. Fraietta, J. Joseph Melenhorst, Elizabeth Veloso, Wei-Ting Hwang, Carl H. June, David L. Porter, Saar Gill

Blood (2024) 144 (Supplement 1): 588.

https://doi.org/10.1182/blood-2024-204197

Published: 2024

Journal Articles

TET2 Regulates Stability of Mismatch Repair Protein MSH6 and Helps Maintain Genomic Stability Independent of Its Dioxygenase Function

Dongxu Jiang, Yahan Zhang, Xiaorong Gu, Daniel J Vail, Jill Durkin, Simon Schlanger, J. Joseph Melenhorst, Jaroslaw Maciejewski, Babal K. Jha

Blood (2024) 144 (Supplement 1): 40.

https://doi.org/10.1182/blood-2024-211171

Published: 2024

Journal Articles

Metabolic Reprogramming By IDH1 Neomorph Epigenetically Guides CAR T Cell Differentiation

Kunho Chung, Dongxu Jiang, Xiaorong Gu, Jie Xu, Céline Grégoire, Beatriz Coutinho De Oliveira, Babal Kant Jha, J. Joseph Melenhorst

Blood (2024) 144 (Supplement 1): 1035.

https://doi.org/10.1182/blood-2024-205836

Published: 2024

Journal Articles

Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Changchun Deng, Paolo F. Caimi, Umar Farooq, Nethrie Idippily, Maria Florencia Giraudo, Jane S. Reese, Sarah Kleinsorge-Block, Daniel Caley, Ryan Stadel, Koen van Besien, Marcos de Lima, Arun Kumar Arunachalam, J. Joseph Melenhorst, David Wald

Blood (2024) 144 (Supplement 1): 94.

https://doi.org/10.1182/blood-2024-206596

Published: 2024

Journal Articles

Low Regimen Therapeutic Strategies to Mitigate TET2 Mutant Clonal Hematopoiesis

Dongxu Jiang, Daniel J Vail, Yahan Zhang, Raziullah Khan, Anand Tiwari, Simon Schlanger, Kunho Chung, Cassandra Gilmour, Xiaorong Gu, Yvonne Parker, J. Joseph Melenhorst, Daniel Lindner, Jaroslaw Maciejewski, Babal K. Jha

Blood (2024) 144 (Supplement 1): 2664.

https://doi.org/10.1182/blood-2024-211363

Published: 2024

Journal Articles

BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function

Blood (2024) 144 (Supplement 1): 909.

https://doi.org/10.1182/blood-2024-202659

Published: 2024

Journal Articles

Single-Cell Multi-Omics Reveals Type-2 Functionality in Maintaining CAR T Cell Longevity Associated with 8-Year Leukemia Remission

Zhiliang Bai, Bing Feng, Susan E. Mcclory, Caroline Diorio, Ziran Zhao, Li Tang, J. Joseph Melenhorst, Carl June, Stephan Grupp, Rong Fan

Blood (2023) 142 (Supplement 1): 352.

https://doi.org/10.1182/blood-2023-179480

Published: 2023

Journal Articles

Signaling Role of Viral Protein Motif and Its Application in CAR T Cell Therapy

Kunho Chung, Wooram Jung, Jae U Jung, J. Joseph Melenhorst

Blood (2023) 142 (Supplement 1): 4815.

https://doi.org/10.1182/blood-2023-186305

Published: 2023

Journal Articles

Co-Stimulatory Signaling Boosts CAR T Cell Efficacy Against CLL

Ziran Zhao, McKensie Collins, Clare Sun, Adrian Wiestner, J. Joseph Melenhorst

Blood (2022) 140 (Supplement 1): 10255–10256.

https://doi.org/10.1182/blood-2022-158614

Published: 2022

Journal Articles

Functional Disruption of TET2-Mediated Cytosine Oxidation in CAR-T Cells Using IDH1 Neomorph

Kunho Chung, Jie Xu, Yaroslav Kaminskiy, Hongxing Sun, Min-Soo Kim, Christopher Petucci, Tong Wang, Rahul M Kohli, J. Joseph Melenhorst

Blood (2022) 140 (Supplement 1): 628–629.

https://doi.org/10.1182/blood-2022-159517

Published: 2022

Journal Articles

Do CARs finally hit the CLL road?

Arnon P. Kater, J. Joseph Melenhorst

Blood (2022) 139 (12): 1775–1776.

https://doi.org/10.1182/blood.2021014492

Published: 2022

Journal Articles

Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells

Blood (2021) 138 (Supplement 1): 166.

https://doi.org/10.1182/blood-2021-152664

Published: 2021

Journal Articles

Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19

Blood (2021) 138 (Supplement 1): 167.

https://doi.org/10.1182/blood-2021-149477

Published: 2021

Journal Articles

Chronic Lymphocytic Leukemia Actively Induces T-Cell Dysfunction By Contact-Dependent Signaling Via CD24 and CD52

Jaco A. C. Van Bruggen, Fleur Peters, Gaspard Cretenet, J. Joseph Melenhorst, Eric Eldering, Arnon P. Kater

Blood (2021) 138 (Supplement 1): 3714.

https://doi.org/10.1182/blood-2021-152495

Published: 2021

Journal Articles

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

Natalie F. Uy, MD, Edward Pequignot, Noelle V. Frey, MD, Megan Davis, PhD, Elizabeth O. Hexner, MD, Stephen J. Schuster, MD, Saar Gill, MD PhD, Alison W. Loren, MD, Stephan A Grupp, MD PhD, J. Joseph Melenhorst, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Joan Gilmore, BS, Lester Lledo, RN,NP, Wei-Ting Hwang, PhD, Don L. Siegel, MD PhD, Bruce L Levine, PhD, Carl H June, MD, David L. Porter, MD

Blood (2020) 136 (Supplement 1): 30–32.

https://doi.org/10.1182/blood-2020-141224

Published: 2020

Journal Articles

B-CLL Mediated Resistance to CAR T Cell Therapy Via Insufficient Activation Is CAR-Independent

McKensie Collins, BS, Weimin Kong, PhD, Inyoung Jung, BS, Stefan M Lundh, BS, J. Joseph Melenhorst, PhD

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-137638

Published: 2020

Journal Articles

Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome

Qian Zhang, Elena J. Orlando, Hong Y. Wang, Agata M. Bogusz, Xiaobin Liu, Simon F. Lacey, Honore T. Strauser, Selene Nunez-Cruz, Reza Nejati, Paul Zhang, Sarah Brooks, Christopher Watt, J. Joseph Melenhorst, Carl H. June, Stephen J. Schuster, Mariusz A. Wasik

Blood (2020) 136 (17): 1980–1983.

https://doi.org/10.1182/blood.2020005123

Published: 2020

Includes: Supplemental data

Journal Articles

CAR-T and ibrutinib vs CLL: sequential or simultaneous?

Arnon P. Kater, J. Joseph Melenhorst

Blood (2020) 135 (19): 1611–1612.

https://doi.org/10.1182/blood.2020005362

Published: 2020

Journal Articles

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells

Marco Ruella, David M. Barrett, Olga Shestova, Jessica Perazzelli, Avery D. Posey, Jr, Seok Jae Hong, Miroslaw Kozlowski, Simon F. Lacey, J. Joseph Melenhorst, Carl H. June, Saar I. Gill

Blood (2020) 135 (7): 505–509.

https://doi.org/10.1182/blood.2019001859

Published: 2020

Includes: Supplemental data

NARROW

Age-Related Cellular Factors Facilitate TET2 Mutant Clonal Hematopoiesis

Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy

TET2 Regulates Stability of Mismatch Repair Protein MSH6 and Helps Maintain Genomic Stability Independent of Its Dioxygenase Function

Metabolic Reprogramming By IDH1 Neomorph Epigenetically Guides CAR T Cell Differentiation

Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Low Regimen Therapeutic Strategies to Mitigate TET2 Mutant Clonal Hematopoiesis

BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function

Single-Cell Multi-Omics Reveals Type-2 Functionality in Maintaining CAR T Cell Longevity Associated with 8-Year Leukemia Remission

Signaling Role of Viral Protein Motif and Its Application in CAR T Cell Therapy

Co-Stimulatory Signaling Boosts CAR T Cell Efficacy Against CLL

Functional Disruption of TET2-Mediated Cytosine Oxidation in CAR-T Cells Using IDH1 Neomorph

Do CARs finally hit the CLL road?

Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells

Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19

Chronic Lymphocytic Leukemia Actively Induces T-Cell Dysfunction By Contact-Dependent Signaling Via CD24 and CD52

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

B-CLL Mediated Resistance to CAR T Cell Therapy Via Insufficient Activation Is CAR-Independent

Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome

CAR-T and ibrutinib vs CLL: sequential or simultaneous?

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only